Non-Hodgkin Lymphoma News

At 34, I Was Diagnosed With An Incurable Cancer. Here How I Beat The Odds After Being Given 3 Months To Live. - HuffPost

At 34, I Was Diagnosed With An Incurable Cancer. Here How I Beat The Odds After Being Given 3 Months To Live. HuffPost

Beyond the Nodes: Atypical Presentations of Non-Hodgkin's Lymphoma Across Organs - Cureus

Beyond the Nodes: Atypical Presentations of Non-Hodgkin's Lymphoma Across Organs Cureus

Understanding the origins of Hodgkin lymphoma cells could lead to better diagnostics - Medical Xpress

Understanding the origins of Hodgkin lymphoma cells could lead to better diagnostics Medical Xpress

Tony Iommi Lymphoma Battle: How the Black Sabbath Legend Beat Cancer - Oncodaily

Tony Iommi Lymphoma Battle: How the Black Sabbath Legend Beat Cancer Oncodaily

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma - PR Newswire

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma PR Newswire

Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma - CancerNetwork

Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma CancerNetwork

The CRIS Foundation Against Cancer awards an IDIBAPS project to advance research into pediatric - Hospital Clínic Barcelona

The CRIS Foundation Against Cancer awards an IDIBAPS project to advance research into pediatric Hospital Clínic Barcelona

New long-term analysis suggests follicular lymphoma can be cured - Fred Hutchinson Cancer Center

New long-term analysis suggests follicular lymphoma can be cured Fred Hutchinson Cancer Center

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch

FDA Fully Approves Brexucabtagene Autoleucel (Tecartus) for Relapsed or Refractory Mantle Cell Lymphoma - Oncology News Central

FDA Fully Approves Brexucabtagene Autoleucel (Tecartus) for Relapsed or Refractory Mantle Cell Lymphoma Oncology News Central

Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 - Fortune Business Insights

Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 Fortune Business Insights

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete - Nature

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete Nature

T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma - Targeted Oncology

T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma Targeted Oncology

Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report - Frontiers

Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report Frontiers

Miami F Marcus Allen has non-Hodgkin lymphoma, out for season - ESPN

Miami F Marcus Allen has non-Hodgkin lymphoma, out for season ESPN

Discovery of a novel vulnerability in aggressive lymphoma could change future therapy - Medical Xpress

Discovery of a novel vulnerability in aggressive lymphoma could change future therapy Medical Xpress

HyBryte FLASH2 failure leaves Soligenix (NASDAQ: SNGX) facing funding and pipeline risk - Stock Titan

HyBryte FLASH2 failure leaves Soligenix (NASDAQ: SNGX) facing funding and pipeline risk Stock Titan

Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription - Nature

Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription Nature

Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation - Frontiers

Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation Frontiers

Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - Wiley

Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Wiley

Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma - Targeted Oncology

Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma Targeted Oncology

Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma - The ASCO Post

Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma The ASCO Post

Non-Hodgkin Lymphoma: Robert's Story - BMT infonet.org

Non-Hodgkin Lymphoma: Robert's Story BMT infonet.org

Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma - Cleveland Clinic

Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma Cleveland Clinic

FDA Approves CAR-T Therapy for Marginal Zone Lymphoma - Oncology News Central

FDA Approves CAR-T Therapy for Marginal Zone Lymphoma Oncology News Central

Dave Coulier Reveals New Cancer Diagnosis Months After Beating Non-Hodgkin Lymphoma - People.com

Dave Coulier Reveals New Cancer Diagnosis Months After Beating Non-Hodgkin Lymphoma People.com

Bispecifics Rise, ADCs Fall? Top News in Diffuse Large B-Cell Lymphoma at ASH 2025 - Oncology News Central

Bispecifics Rise, ADCs Fall? Top News in Diffuse Large B-Cell Lymphoma at ASH 2025 Oncology News Central

Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial - Nature

Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial Nature